|
1
|
Allemani C, Weir HK, Carreira H, Harewood
R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A,
et al CONCORD Working Group: Global surveillance of cancer survival
1995–2009: Analysis of individual data for 25,676,887 patients from
279 population-based registries in 67 countries (CONCORD-2).
Lancet. 385:977–1010. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dixon M, Mahar AL, Helyer LK,
Vasilevska-Ristovska J, Law C and Coburn NG: Prognostic factors in
metastatic gastric cancer: Results of a population-based,
retrospective cohort study in Ontario. Gastric Cancer. 19:150–159.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Strong VE, Wu AW, Selby LV, Gonen M, Hsu
M, Song KY, Park CH, Coit DG, Ji JF and Brennan MF: Differences in
gastric cancer survival between the U.S. and China. J Surg Oncol.
112:31–37. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu W, Yang Z and Lu N: Molecular targeted
therapy for the treatment of gastric cancer. J Exp Clin Cancer Res.
35:12016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yarden Y and Pines G: The ERBB network: At
last, cancer therapy meets systems biology. Nat Rev Cancer.
12:553–563. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Terashima M, Kitada K, Ochiai A, Ichikawa
W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H and Sasako
M: ACTS-GC Group: Impact of expression of human epidermal growth
factor receptors EGFR and ERBB2 on survival in stage II/III gastric
cancer. Clin Cancer Res. 18:5992–6000. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang W, Raufi A and Klempner SJ: Targeted
therapy for gastric cancer: Molecular pathways and ongoing
investigations. Biochim Biophys Acta. 1846:232–237. 2014.PubMed/NCBI
|
|
8
|
Fontana E and Smyth EC: Novel targets in
the treatment of advanced gastric cancer: A perspective review.
Ther Adv Med Oncol. 8:113–125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang Z, Li C, Li F and Wang X: EGFR gene
copy number as a prognostic marker in colorectal cancer patients
treated with cetuximab or panitumumab: A systematic review and meta
analysis. PLoS One. 8:e562052013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pirker R, Pereira JR, von Pawel J,
Krzakowski M, Ramlau R, Park K, De Marinis F, Eberhardt WE,
Paz-Ares L, Störkel S, et al: EGFR expression as a predictor of
survival for first-line chemotherapy plus cetuximab in patients
with advanced non-small-cell lung cancer: Analysis of data from the
phase 3 FLEX study. Lancet Oncol. 13:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Higaki E, Kuwata T, Nagatsuma AK, Nishida
Y, Kinoshita T, Aizawa M, Nitta H, Nagino M and Ochiai A: Gene copy
number gain of EGFR is a poor prognostic biomarker in gastric
cancer: Evaluation of 855 patients with bright-field dual in situ
hybridization (DISH) method. Gastric Cancer. 19:63–73. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK
and Kim WH: EGFR in gastric carcinomas: Prognostic significance of
protein overexpression and high gene copy number. Histopathology.
52:738–746. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Friedman JM and Jones PA: MicroRNAs:
Critical mediators of differentiation, development and disease.
Swiss Med Wkly. 139:466–472. 2009.PubMed/NCBI
|
|
16
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X, Zhang Z, Yu M, Li L, Du G, Xiao W
and Yang H: Involvement of miR-20a in promoting gastric cancer
progression by targeting early growth response 2 (EGR2). Int J Mol
Sci. 14:16226–16239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li H, Xie S, Liu X, Wu H, Lin X, Gu J,
Wang H and Duan Y: Matrine alters microRNA expression profiles in
SGC-7901 human gastric cancer cells. Oncol Rep. 32:2118–2126.
2014.PubMed/NCBI
|
|
19
|
Riquelme I, Tapia O, Leal P, Sandoval A,
Varga MG, Letelier P, Buchegger K, Bizama C, Espinoza JA, Peek RM,
et al: miR-101-2, miR-125b-2 and miR-451a act as potential tumor
suppressors in gastric cancer through regulation of the
PI3K/AKT/mTOR pathway. Cell Oncol. 39:23–33. 2016. View Article : Google Scholar
|
|
20
|
El-Daly SM, Abba ML, Patil N and Allgayer
H: miRs-134 and −370 function as tumor suppressors in colorectal
cancer by independently suppressing EGFR and PI3K signaling. Sci
Rep. 6:247202016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeng Y, Fu M, Wu GW, Zhang AZ, Chen JP,
Lin HY, Fu YA, Jia J, Cai ZD, Wu XJ, et al: Upregulation of
microRNA-370 promotes cell apoptosis and inhibits proliferation by
targeting PTEN in human gastric cancer. Int J Oncol. 49:1589–1599.
2016.PubMed/NCBI
|
|
22
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M,
et al: Combinatorial microRNA target predictions. Nat Genet.
37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang S, Luo A, Hao X, Lai Z, Ding T, Ma X,
Mayinuer M, Shen W, Wang X, Lu Y, et al: Peroxiredoxin 2 inhibits
granulosa cell apoptosis during follicle atresia through the NFKB
pathway in mice. Biol Reprod. 84:1182–1189. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Weng X, Zhang H, Ye J, Kan M, Liu F, Wang
T, Deng J, Tan Y, He L and Liu Y: Hypermethylated Epidermal growth
factor receptor (EGFR) promoter is associated with gastric cancer.
Sci Rep. 5:101542015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Weiss GJ, Bemis LT, Nakajima E, Sugita M,
Birks DK, Robinson WA, Varella-Garcia M, Bunn PA Jr, Haney J,
Helfrich BA, et al: EGFR regulation by microRNA in lung cancer:
Correlation with clinical response and survival to gefitinib and
EGFR expression in cell lines. Ann Oncol. 19:1053–1059. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Uhlmann S, Mannsperger H, Zhang JD, Horvat
EA, Schmidt C, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K,
et al: Global microRNA level regulation of EGFR-driven cell-cycle
protein network in breast cancer. Mol Syst Biol. 8:5702012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mlcochova J, Faltejskova P, Nemecek R,
Svoboda M and Slaby O: MicroRNAs targeting EGFR signalling pathway
in colorectal cancer. J Cancer Res Clin Oncol. 139:1615–1624. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen T, Gao F, Feng S, Yang T and Chen M:
MicroRNA-370 inhibits the progression of non-small cell lung cancer
by downregulating oncogene TRAF4. Oncol Rep. 34:461–468.
2015.PubMed/NCBI
|
|
32
|
Yungang W, Xiaoyu L, Pang T, Wenming L and
Pan X: miR-370 targeted FoxM1 functions as a tumor suppressor in
laryngeal squamous cell carcinoma (LSCC). Biomed Pharmacother.
68:149–154. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Meng F, Wehbe-Janek H, Henson R, Smith H
and Patel T: Epigenetic regulation of microRNA-370 by interleukin-6
in malignant human cholangiocytes. Oncogene. 27:378–386. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen XP, Chen YG, Lan JY and Shen ZJ:
MicroRNA-370 suppresses proliferation and promotes endometrioid
ovarian cancer chemosensitivity to cDDP by negatively regulating
ENG. Cancer Lett. 353:201–210. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chang KW, Chu TH, Gong NR, Chiang WF, Yang
CC, Liu CJ, Wu CH and Lin SC: miR-370 modulates insulin receptor
substrate-1 expression and inhibits the tumor phenotypes of oral
carcinoma. Oral Dis. 19:611–619. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lo SS, Hung PS, Chen JH, Tu HF, Fang WL,
Chen CY, Chen WT, Gong NR and Wu CW: Overexpression of miR-370 and
downregulation of its novel target TGFβ-RII contribute to the
progression of gastric carcinoma. Oncogene. 31:226–237. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fan C, Liu S, Zhao Y, Han Y, Yang L, Tao
G, Li Q and Zhang L: Upregulation of miR-370 contributes to the
progression of gastric carcinoma via suppression of FOXO1. Biomed
Pharmacother. 67:521–526. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xie J, Chen M, Zhou J, Mo MS, Zhu LH, Liu
YP, Gui QJ, Zhang L and Li GQ: miR-7 inhibits the invasion and
metastasis of gastric cancer cells by suppressing epidermal growth
factor receptor expression. Oncol Rep. 31:1715–1722.
2014.PubMed/NCBI
|
|
39
|
Liu G, Jiang C, Li D, Wang R and Wang W:
MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in
gastric cancer. Tumour Biol. 35:9801–9806. 2014. View Article : Google Scholar : PubMed/NCBI
|
